You are here

Europe

European Equities: Rolling Over…Or Overdue?

European Equities: Rolling Over…Or Overdue?

By Dana Lyons of My401kPro.com

In terms of global reach, the post-February equity rally has been a fairly broad advance. Some markets, most notably the U.S., have resumed their former relative strength while other regions, like emerging markets and Latin America, have seen strong mean-reversion bounces from very oversold levels, One region conspicuously lagging during this rally, however, has been Europe.

Frontrunning: April 6

  • Cruz, Sanders score decisive victories in Wisconsin (Reuters)
  • Clinton Can’t Get to New York Fast Enough After New Sanders Win (BBG)
  • Trump, Clinton Have Single-Digit Leads in Pennsylvania (BBG)
  • Panama law firm says data hack was external, files complaint (Reuters)
  • ‘Panama Papers’ Puts Spotlight on Boom in Offshore Services (WSJ)
  • Barclays partners with Goldman-backed bitcoin payments app (FT)
  • China Inc. Scraps $7 Billion of Bond Offerings as Defaults Rise (BBG)
  • Activists Reap Olive Garden Bounty (WSJ)

Stocks Rebound In Calm Trading On Back Of Stronger Crude, Dollar

Stocks Rebound In Calm Trading On Back Of Stronger Crude, Dollar

Unlike yesterday's overnight session, which saw some substantial carry FX volatility and tumbling European yields in the aftermath of the TSY's anti-inversion decree, leading to a return of fears that the next leg down in markets is upon us, the overnight session has been far calmer, assisted in no small part by the latest China Caixin Services PMI, which rose from 51.2 to 52.2 (even if the employment index dropped to a three year low, suggesting China's labor problems are only just starting).

The ECB’s Monetary Policy Is Now Creating a Rush Into Derivatives

Submitted by Mike Krieger of Libertyblitzkrieg

The ECB’s Monetary Policy Is Now Creating a Rush Into Derivatives

One of the most catastrophic things central banks have done in the post financial crisis period is destroy financial markets. Investors are no longer investors, they’re merely helpless rats running around the lunatic central planning maze desperately attempting to survive by front running the latest round of central bank purchases.

As Pfizer-Allergan Sinks, These "Inversion" Deals Could Be Next

As Pfizer-Allergan Sinks, These "Inversion" Deals Could Be Next

While the surge in Q1 market volatility has had a dramatic impact on asset prices, and led to some unprecedented central bank interventions to stabilize markets, one product that has seen a dramatic hit and has yet to rebound, is M&A.

According to BofA, North American M&A volumes declined again in March, falling to $107bn from $140bn in February, $157bn in January and the recent peak of $410bn in November of last year.

Pages